AHR and Hypertension: There are several protective mechanisms by which maternal DMB therapy moderates hypertension programmed by combined HFR+TCDD exposure, such as increasing NO bioavailability, balancing the RAS, antagonizing AHR signaling, and restoring the gut microbiota.